Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.

ABSTRACT:

Background

Greater understanding of the molecular classification of breast cancer has permitted the development of rational drug design strategies. In a phase I clinical trial setting, molecular profiling with next-generation sequencing of individual tumour samples has been employed to guide treatment.

Methods

We conducted a retrospective evaluation of clinical outcomes of patients with metastatic breast cancer (MBC) treated in phase I clinical trials at our institution to assess the benefit of molecularly matched compared to non-matched treatments.

Results

A total of 97 consecutive patients with MBC were enrolled onto ≥1 trial between 2009 and 2015. Fourteen patients participated in multiple trials, and a total of 113 trial encounters were reviewed in this retrospect

SUBMITTER: O'Carrigan B 

PROVIDER: S-EPMC6203714 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature